Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bone Biologics Corp Director's Dealing 2023

Mar 8, 2023

35440_dirs_2023-03-08_55418c80-f73a-4c90-8a4e-4cf9a9a420e4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2022-08-23

Reporting Person: Angle Siddhesh Rajendra (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-08-23 Non-Employee Stock Option $1.61 A 36845 Acquired 2027-08-23 Common Stock (36845) Direct

Footnotes

F1: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant.